To end the epidemic, prevention plays a central role. We’re aiming for a future where everyone who needs or wants HIV prevention has an option that works well for them.

To make that a reality, we’re advancing innovations that are both long-acting and highly effective, including a new long-acting option that was recently approved in the United States. This new choice expands on our decades of innovation across HIV, including our introduction of the first once-daily oral medication for pre-exposure prophylaxis (PrEP). PrEP means routinely taking prescription medicine before being exposed to HIV to help reduce the chances of being infected by the virus.

To accelerate progress, we’re committed to expanding access to long-acting prevention to people around the world, working closely with partners from all sectors. Our approach to access begins in clinical development, designing clinical trials in partnership with the community and targeting populations that are most in need of new choices. Then, following approval, our strategy is guided by four priorities: delivering a therapy with speed, at sufficient volume, at prices to enable widespread availability and working in partnership with private and public organizations across the global health ecosystem.

And, there’s more: Innovation across prevention is going full speed at Gilead. We are aiming for even longer acting options, including those requiring only once-a-year dosing. We won’t stop until the epidemic is over, for everyone.

Gilead researchers have developed therapies that are leading the global response to HIV. And, thanks to incredible progress across the HIV treatment community, effective treatments that suppress viral replication are now broadly available. This includes advancements such as modern once-daily single tablet regimens and long-acting injectable options that enable individuals who are taking and staying on treatment to lead longer and healthier lives.

These innovations, which are aimed to meet the changing needs and preferences of diverse communities impacted by the virus, are helping improve antiretroviral treatment effectiveness and engagement in care.

Nevertheless, HIV persists as a serious public health challenge. We recognize that ending the epidemic requires close partnership with the entire HIV community. By exploring how our medicines work in communities shouldering a disproportionate burden of the epidemic and advancing innovative treatment strategies that could drive more equitable and comprehensive access to HIV care, our goal is to bring forward effective therapy options to everyone who needs them.

HIV treatment and prevention is entering a new era where more therapeutic options are emerging for people living with HIV and those who need or want PrEP.

Once-daily single tablet regimens have helped bring radical change in the outlook for people living with HIV. Yet significant gaps in care still remain. Some people face challenges with adherence due to limited treatment options or regimen complexity. In certain areas around the globe, taking daily pills may also be a stigmatizing burden.

Our goal is to discover and develop innovative HIV medicines. We believe the next wave of innovation in HIV includes long-acting options that are aiming to help address the differentiated needs and preferences of the diverse range of individuals and communities affected by the epidemic.

Curing HIV remains the ultimate aspiration of Gilead’s research and development efforts.

While HIV treatment has advanced dramatically over the past three decades, antiretroviral therapy (ART) remains the standard of care. Since the start of the epidemic, we’ve been pursuing potential pathways to achieve a cure for HIV that’s efficacious, scalable and accessible, and that results in permanent freedom from HIV for people who have it.

Our efforts toward a cure are beginning to show incremental but impactful progress. We’re working with partners on a “clear and control” approach aimed at clearing or reducing the HIV reservoir in a person’s cells, and then using the person’s immune system to control any remaining HIV. This study’s regimen may deliver prolonged periods for people with HIV to safely live without ART. More importantly for long-term progress in the cure field, the study will also help inform what is needed to drive progress toward the ultimate aspiration of a cure.

We know it will take more than medicine alone to end the HIV epidemic for everyone, everywhere.

The social, cultural and structural barriers that exist in our world need to be addressed as part of global HIV elimination efforts. We have a long history of working alongside the HIV community to achieve more equitable access to HIV care and services. Our cutting-edge research programs focus on the needs of people who are disproportionately impacted by HIV and traditionally underrepresented in studies. And through unique partnerships and access programs, we're working to improve HIV treatment and prevention education, support systems and policies that help facilitate broader uptake of medications and eliminate stigma and other barriers to care.

Today we are one of the largest private funders of non-profit HIV programs in the world. However, our work isn’t done until we have positively impacted the lives of all the people and communities impacted by HIV.